Laquinimod
-
Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage; Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration
-
New data presented at ECTRIMS shows that laquinimod has an effect on both inflammation and the underlying mechanisms associated with disease progression in multiple sclerosis
-
Teva is planning to commence clinical trials in Huntington`s disease and primary progressive multiple sclerosis (PPMS)
-
Teva will initiate a further clinical trial in multiple sclerosis (LIBRETTO)
Tasquinimod
-
Phase III 10TASQ10 study is proceeding as planned; the primary analysis of progression-free survival (PFS) and survival (OS) is expected in 2014
-
Active Biotech received a milestone payment of EUR 12 M from Ipsen
ANYARA
-
Detailed analysis provides further support for ANYARA`s efficacy in a biomarker-defined sub-group of renal cell cancer patients; the result from the Phase II/III study was presented at the 2013 European Cancer Congress
Paquinimod (57-57)
-
Evaluation under way of clinical trial in systemic sclerosis
ISI
-
Project proceeding according to plan
Financial summary
| SEK M | Q3 | Jan - Sept | Jan - Dec | |||||
| 2013 | 2012 | 2013 | 2012 | 2012 | ||||
| Net sales | 107.0 | 39.8 | 111.9 | 136.4 | 227.9 | |||
| Operating loss | 27.9 | -48.2 | -128.6 | -168.7 | -163.2 | |||
| Profit/Loss after tax | 29.2 | -51.6 | -130.0 | -175.1 | -175.0 | |||
| Profit/loss per share | 0.39 | -0.75 | -1.77 | -2.54 | -2.54 | |||
For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95
Hans Kolam, CFO
Tel: +46 (0)46-19 20 44
Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00
The report is also available at www.activebiotech.com
Active Biotech AB Interim Report January – September 2013
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Thomson Reuters ONE
HUG#1741192